DEA Schedules Hearing On Proposed Ban Of Psychedelic Compounds With Therapeutic Potential
The Drug Enforcement Administration (DEA) has announced a 10-day hearing to deliberate on the potential ban of two psychedelic compounds, 2,5-dimethoxy-4-iodoamphetamine (DOI) and 2,5-dimethoxy-4-chloroamphetamine (DOC). As reported by Green Market Report, the hearing, scheduled to run from November 12 to November 22, 2024, with a final meeting on November 25, will take place at the DEA hearing facility in Arlington, Virginia.
Compounds At The Center Of Controversy
The proposed rulemaking seeks to place DOI and DOC under Schedule I of the Controlled Substances Act, a classification reserved for substances deemed to have a high potential for abuse with no accepted medical use. These compounds, vital tools for scientists studying serotonin receptors, have been instrumental in over 900 research articles, showing promise in various therapeutic areas, including pain management, anxiety and depression treatment and overdose prevention. Their current …